China weighs banning foreign acquisitions of critical biopharma platforms
China is preparing a draft policy to restrict foreign investors' acquisition of critical biopharma platforms, according to Fierce Biotech. The move comes as Washington steps up efforts to tighten cross-border life sciences deals involving Chinese assets. Beijing is seeking to strengthen its grip on biomedical innovation.
Read the full story at FierceBiotech
IASummary generated by artificial intelligence from a story by FierceBiotech. It may contain errors: the original source prevails.
